OTCBB: IMUC and BioWa, Inc. (BioWa) today announced that they have entered into a agreement to provide IMUC with access to BioWa’s patented POTELLIGENT^® Technology platform for the development of antibody-dependent cellular cytotoxicity (OTC:ADCC) enhanced antibodies.
The Bottom line: Under the agreement BioWa will receive the right to certain antibody technology from IMUC and selected option rights to IMUC antibodies using the POTELLIGENT^® Technology. POTELLIGENT technology improves potency and efficacy of antibody therapeutics, by enhancing ADCC, one of the major mechanisms of action for antibody therapeutics; involving the reduction of the amount of fucose in the carbohydrate structure of an antibody using a proprietary fucosyl transferase-knockout CHO cell line as a production cell. Research shows that PT dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo. IMUC.OB recently started a P2 trial of lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for newly diagnosed glioblastoma.
- At the (6/2/11) open, IMUC.OB is up $0.07 (3.78%) to $1.92 in a down market.